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Systematic assessment of outcomes following a genetic
diagnosis identified through a large-scale research study into
developmental disorders
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PURPOSE: The clinical and psychosocial outcomes associated with receiving a genetic diagnosis for developmental disorders are
wide-ranging but under-studied. We sought to investigate outcomes from a subset of families who received a diagnosis through
the Deciphering Developmental Disorders (DDD) study.
METHODS: Individuals recruited through the Peninsula Clinical Genetics Service who received a confirmed genetic diagnosis
through the DDD study before August 2019 (n= 112) were included in a clinical audit. Families with no identified clinical outcomes
(n= 16) were invited to participate in semistructured telephone interviews.
RESULTS: Disease-specific treatment was identified for 7 probands (6%), while 48 probands (43%) were referred for further
investigations or screening and 60 probands (54%) were recruited to further research. Just 5 families (4%) opted for prenatal testing
in a subsequent pregnancy, reflecting the relatively advanced maternal age in our cohort, and 42 families (38%) were given disease-
specific information or signposting to patient-specific resources such as support groups. Six interviews were performed (response
rate= 47%) and thematic analysis identified four major themes: reaching a diagnosis, emotional impact, family implications, and
practical issues.
CONCLUSION: Our data demonstrate that receiving a genetic diagnosis has substantial positive medical and psychosocial
outcomes for the majority of patients and their families.
Genetics in Medicine (2021) 23:1058–1064; https://doi.org/10.1038/s41436-021-01110-3
INTRODUCTION
Developmental disorders describe a group of conditions that result
in delayed cognitive and/or atypical physical development in
children under 5 years of age.1 While a wide range of etiologies are
recognized, up to 80% of cases are predicted to be due to an
underlying monogenic or chromosomal cause.2,3 Although stan-
dard clinical approaches are only able to identify diagnoses for less
than half of affected individuals,4 family-based genome-wide
sequencing studies have substantially increased the diagnostic
yield over the last decade.5,6 The benefits of receiving a genetic
diagnosis can be broad, from counseling the family about their
recurrence risk and offering preimplantation/prenatal testing,
through to identifying diagnosis-specific treatments for the
proband.7,8 However, while a few recent studies have investigated
the outcomes for families who received a clinical diagnosis through
exome and genome sequencing, they mostly comprise case
reports and small case series.9 To date, no research has system-
atically evaluated outcomes in a large cohort of patients who
obtained their diagnosis through a genomic research study.
The Deciphering Developmental Disorders (DDD) study4 was
created with the aim of using high-resolution genomic testing
methods to investigate the genetic etiology of abnormal
development. From 2011 to 2015, the study recruited ~13,500
children with severe but previously undiagnosed developmental
disorders, and their parents, from 23 National Health Service (NHS)
Regional Genetics Services across the UK and one in Eire.10,11
Using a combination of high-resolution array comparative
genomic hybridization (array-CGH) testing and trio exome
sequencing,12,13 the DDD study has identified plausible genetic
diagnoses in around 40% of children and communicated these
findings back to their local genetics teams for validation and
discussion with the families.11 The DDD study thus provides an
ideal cohort in which to systematically evaluate clinical outcomes
arising from a pediatric genomics research study.
Here we describe a pilot study investigating the clinical and
psychosocial outcomes of receiving a genetic diagnosis in a subset
of 112 DDD participants from a single UK center. Our study will
not only help better understand the wider impact of receiving a
diagnosis for the patient and their family, but also inform larger
systematic outcomes studies.
MATERIALS AND METHODS
We used a mixed methods approach to gather outcome data on DDD
families, which combined a quantitative clinical audit and a series of
semistructured qualitative interviews. Eligibility for inclusion in the audit
was defined as any individual recruited to the DDD study through the
Peninsula Clinical Genetics Service (which covers Devon and Cornwall) for
whom the DDD study had identified a definite genetic diagnosis (Fig. 1).
Eligible individuals were identified through the DECIPHER database,14 and
linked-anonymized DECIPHER IDs were used by the local team to connect
the genetic diagnosis with the patient records for each proband. We
developed a pro forma for collecting standardized information during the
clinical audit from the local NHS Clinical Genetics records relating to
outcomes; this included treatments, further investigations, reproductive
decisions, adverse events, recruitment to further genetic research studies,
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and the information given to the patient/parents at the time of diagnosis
(Supplementary Table 1). Disease-specific treatments were identified
through review of correspondence in clinical records and through
published literature searching. We also used the Unique patient support
website15 and other online resources to identify whether gene
disease–specific information was available, such as a leaflet or document
written for patients and their families.
Following the clinical audit, families in whom we were unable to identify
any outcomes were invited to participate in a semistructured interview. We
designed a questionnaire (Supplementary Table 2) to identify personal,
family, and wider outcomes that were not possible to assess through the
audit. Interviews were performed over the telephone and recorded to
enable transcription. A deductive thematic approach was used to analyze
the qualitative data to identify major and minor themes.
RESULTS
We identified 112 diagnosed probands who were eligible for
inclusion in the clinical audit (Fig. 1). The probands ranged in age
at recruitment from 3 to 44 years (median= 8.7), which is
somewhat older than the rest of the cohort (median= 6.7, p=
0.0002), and the age of the parents at the birth of the proband
ranged from 17 to 66 (median= 31), which is representative of the
rest of the DDD cohort (median= 31, p= 0.3). A range of
confirmed diagnoses were identified, including 97 dominant (of
which 81 were de novo), 12 recessive, and 3 X-linked recessive.
Within the cohort, variants were classed as pathogenic or likely
pathogenic following the Association for Clinical Genomic Science
(ACGS) best practice guidelines for variant classification16 and
validated in an accredited laboratory. Diagnostic variants were
identified in 85 different genes, with diagnoses in 16 genes being
causative in more than one unrelated individual.
Clinical outcomes identified in the audit (or subsequent
interview) are summarized in Fig. 2. Seven probands (6%) received
a diagnosis for which a disease-specific treatment was known
(Table 1). Of these, 5/7 probands had treatable epilepsy as part of
their phenotype, where knowledge of the specific molecular cause
allows the correct drug to be rapidly selected from those
available.17 Of the five probands with treatable epilepsy, four
received a change in treatment following their genetic diagnosis.
One proband received an expedited hematopoietic stem cell
transplant to treat bone marrow failure, and another may receive
treatment for Parkinsonism when age appropriate.
A total of 43 further diagnostic clinical investigations and 40
referrals to different medical specialties were requested for 48
individuals (43%). These included requests for reviews of previous
n=13,612
Participants recruited to the DDD Study
n=471
Participants recruited to DDD through the
Royal Devon and Exeter Foundation Trust
Clinical Genetics Service
n=114





Individuals with one or more clinical
outcomes identified
n=16
Individuals with no clinical
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Individuals who have moved







Participants for whom the DDD
Study has not yet identified a
definite genetic diagnosis
Fig. 1 Flowchart showing recruitment process for the clinical audit and the semistructured interviews. DDD Deciphering Developmental
Disorders study.
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n=11 Tests performed by
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Fig. 2 Flowchart demonstrating outcomes identified primarily through the clinical audit. BINGO Brain and Behaviour in Intellectual
Disability of known Genetic Origin study, CVS chorionic villus sampling, GP general practitioner, IMAGINE ID Intellectual Disability and Mental
Health: Assessing the Genomic Impact on Neurodevelopment study, PGD pre-implantation genetic diagnosis.
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scans (n= 5), ophthalmology assessments (n= 9), and cardiac
investigations (n= 11), and referrals for ongoing screening by
radiology (n= 7), ophthalmology (n= 8), and endocrinology (n=
5) departments. Many of these individuals did not present with
problems requiring those medical specialties prediagnosis. Infor-
mation relating to the results of these screening referrals was not
assessed through this audit. Furthermore, we were able to identify
two participants for whom the diagnosis prevented unnecessary
diagnostic interventions, including growth investigations and a
magnetic resonance imaging (MRI) scan under general anesthetic.
A total of 60 families (53%) were recruited to additional research
studies following their diagnosis, including the Intellectual
Disability and Mental Health: Assessing the Genomic Impact on
Neurodevelopment (IMAGINE ID) study18 (n= 43) and the Brain
and Behaviour in Intellectual Disability of known Genetic Origin
(BINGO) study19 (n= 6). Gene or disease-specific information in
the form of a patient information leaflet or document was given to
42 families (37.5%). A total of 27 families (24%) were signposted to
sources of additional information, including the Unique website
(n= 5), Facebook groups (n= 8), and disease-specific support
groups (n= 4). Contact between the families of probands with the
same diagnosis was facilitated for ten families.
Discussions with parents regarding reproductive choices were
documented in the notes of 45 families, which represents 83% of
couples where the mother was of reproductive age (<45 years) at
the point of receiving the proband’s diagnosis. The audit
identified three cases in which the proband’s diagnosis was used
to inform invasive prenatal testing procedures in subsequent
pregnancies, all of which were negative. In a further two cases, the
couples chose to have preimplantation genetic diagnosis; treat-
ment for one couple is still ongoing, and the second couple now
have a healthy child. These five families represent 9% of the
families in which the mother was of reproductive age.
The audit identified one adverse effect of receiving a diagnosis.
The proband showed distress during their results appointment upon
learning that the diagnosis would likely lead to additional symptoms
and screening in the future, requiring further face-to-face and
telephone consultations to manage their distress and anxiety.
We were unable to identify any outcomes beyond the diagnosis
itself for 16/112 individuals in the clinical audit (Fig. 1). Of these,
one proband was deceased, so 15 families were invited to
participate in a telephone interview. Seven initial responses were
received (47% response rate) from parents of patients, and six
interviews were conducted. The probands in these six families had
all received a diagnosis of a de novo variant identified through the
DDD study. Thematic analysis identified four major themes and a
range of subthemes, shown in Fig. 3, and selected quotes from
interview transcripts are given in Supplementary Table 3.
All interview participants were positive about having partici-
pated in the DDD study, and one participant described a
treatment change that had arisen for their child following the
diagnosis that was not identified in the clinical audit (included in
Fig. 2 and Table 1). The main motivation for participating in the
study was finding an answer for their child’s problems, with many
describing a long and complicated search for a diagnosis.20
Parents felt a sense of responsibility to obtain a diagnosis, and also
described secondary altruistic motivations. Two families described
the negative impact of previous incorrect diagnoses, with one
interview participant reporting difficulty in accepting a diagnosis
that did not seem to fit the child’s problems. Most participants
reported feelings of guilt about their child’s difficulties, and upon
learning that the genetic variant has arisen de novo, some
participants reported that their guilt had reduced. While all
participants acknowledged that their child’s diagnosis had
provided clarity as to the cause of their symptoms, for some,
the diagnosis also brought uncertainty, particularly among parents
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All participants discussed the impact of their child’s diagnosis
on other family members, and valued the relevance of the
information for the wider family. Three participants raised
the topic of further children and provided different perspectives
of the decision-making process faced by families without a
diagnosis. One participant described a subsequent pregnancy
before the final diagnosis as an extremely challenging time; the
lack of clarity about the cause of her child’s symptoms negatively
impacting her experience of the subsequent pregnancy. Another
participant described how not having a diagnosis previously had
impacted on the couple’s decision not to have another child.
Despite feeling generally positive about receiving a diagnosis,
all six interviewees explained that the level of day-to-day needs of,
and support for, their child had not substantially changed
following the diagnosis. Nonetheless, parents did feel that the
process of applying for support had been streamlined by having a
definitive genetic diagnosis rather than a list of symptoms. One
participant described the diagnosis as being key to accessing
specialist educational support, which significantly improved the
child’s wellbeing. There was disparity among the interview
participants about accessing support networks; interestingly,
those who were aware of similarly affected children often did
not wish to make contact due to fear of overwhelming the other
family or because they did not perceive a benefit to such a
meeting.
DISCUSSION
We have evaluated the clinical and psychosocial outcomes in a
subset of 112 families from a single UK center who received a
genetic diagnosis from the DDD study. We were able to identify
diagnosis-specific outcomes in 97/112 (87%) individuals, including
direct medical outcomes for the proband in 45% of cases, such as
diagnosis-specific treatments (n= 7) and referral for additional
investigations or screening (n= 43). Those patients who received
a diagnosis-specific treatment experienced clinical improvements
in symptom control, demonstrating the value and importance of
tailored treatments,21,22 and emphasizing the need for continued
research into this field. In contrast to treatment of existing
phenotypes, referral for additional screening often related to
monitoring and managing phenotypes that had not yet emerged,
something that caused anxiety in at least once case.
Some families (n= 5) were able to access prenatal testing and
preimplantation genetic diagnosis treatments, which would not
have been available to them without the diagnosis. We anticipate
that many more would have accessed this option had the parents
been of reproductive age at the point of receiving the diagnosis.
We also expect that this result is likely to have been influenced by
the high proportion of families with diagnostic de novo variants in
our cohort. Accurate genetic diagnosis of developmental disorders
empowers individuals to make informed and value-based
reproductive decisions, highlighting the importance of a diagnosis
for family planning purposes.23,24 For many participants (53%),
receiving a diagnosis meant they met the eligibility criteria for
further research studies and subsequent successful recruitment
suggests that they had a positive perception of genetic research
following their involvement in the DDD study. The audit identified
46 participants who had been included in a scientific publication,
demonstrating the benefits of novel diagnoses to the scientific
community. Additionally, we found that around a third of
participants were given patient-focused information related to
the diagnosis while others were signposted to sources of
additional information; both are ways to reinforce complex
genetic information. In 55 cases, where patient-focused informa-
tion was not available, scientific literature was instead given to the
family where appropriate. These findings highlight and support
the need for continued development of patient-focused informa-
tion to be developed as new developmental disorders are
identified.
Our semistructured interviews focused on families in whom no
clinically relevant outcomes could be identified from the clinical
audit. Although this strategy left us with just 16 eligible families,
we judged that it would maximize our chances of identifying
























Fig. 3 Cluster diagram representing the four major themes and their respective subthemes identified through thematic analysis of the
interview transcript data. DDD Deciphering Developmental Disorder study.
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who might feel less favorably toward genetics research and who
might thus offer a different and useful perspective. Nonetheless, a
good response rate of nearly 50% among those invited to
interview suggests high engagement and motivation even in
these families for whom no clinical outcomes were observed.
Moreover, through the course of just six interviews, we identified
an additional family in whom diagnosis enabled a specific
treatment. This suggests that we underascertained outcomes
based on a clinical audit of genetics notes and indicates that
further research using extended hospital notes or additional
interviews is needed to fully explore outcomes.
All participants reported feeling positively about their involve-
ment in the DDD study, and while recognizing the potential for
bias given that these families all received a diagnosis, this finding
supports the value for patients and families of being involved in
genetics research. Four main themes and further subthemes were
identified following thematic analysis, although there is significant
overlap between the themes (Fig. 3 and Supplementary Table 3).
The observed sense of parental responsibility to find an
explanation for their child’s symptoms links to a reported sense
of failure when standard clinical pathways fail to find an answer.25
Secondary altruistic motivations demonstrate the different expec-
tations families have of participating in genetic research studies.26
Experiences shared by interview participants about the diagnostic
odyssey emphasized the complex interplay between their child’s
phenotypic symptoms, creating an emotional burden.20 One
family described their experience with earlier misdiagnoses,
demonstrating the widespread negative impact on the patient
and the wider family of incorrect diagnoses. This further reflects a
theme of parental “gut instinct”;27 some parents reported feeling
strongly that a diagnosis was incorrect, but did not feel qualified
to question or challenge the medical opinion,28 potentially
increasing self-doubt and further delaying a correct diagnosis.29
Most interview participants described feeling significant levels
of guilt about their child’s problems. For them, finally knowing the
underlying cause changed this guilt, demonstrating the value of
timely diagnosis.30,31 However, this outcome is partly influenced
by the fact that all interviewed families had a diagnostic de novo
variant; higher levels of parental guilt have been linked to
inherited autosomal recessive or X-linked diagnoses in children.30
Relief was a frequently reported emotional impact associated with
receiving a diagnosis. Participants associated relief with feelings of
validation for their child’s difficulties and their own concerns.
Relief has also been linked to parental empowerment,32 showing
the interplay between parental guilt and relief, and highlighting
the value of finally obtaining a diagnosis. Concern for other family
members also demonstrates that the impact of not having a
diagnosis extends beyond the individual patient, and reflects the
importance of a family-based approach in managing highly
penetrant monogenic conditions.33 Being able to accurately clarify
and communicate risks to family members was highly valued by
the interview participants, with emotional responses reflecting a
sense of parental responsibility in providing information for the
whole family.25 Interview participants differed in their decision to
have another child and their uptake of testing during subsequent
pregnancies, highlighting the complexities of such decisions. The
interviews demonstrate that these emotions can last for a number
of years, and can resurface in the future, emphasizing the
emotional burden felt by parents without a diagnosis. One
participant’s reflection that having an earlier diagnosis might have
influenced the decision to have another child emphasizes the
challenges faced in reproductive decision-making in a rapidly
changing field.
Limitations
Our findings are limited by a few practicalities. First, although
genetic and phenotypic data on DDD families is managed
centrally and shared with clinical teams via the DECIPHER
database, a linked-anonymized system of IDs is used and
researchers do not have access centrally to personal identifiers,
which are maintained inside local NHS clinics. We therefore
limited our sample group to one UK Regional Genetics Service, so
our conclusions may not be representative of different services or
geographies. Second, medical records at the Royal Devon and
Exeter NHS Foundation Trust are not currently electronic, and
clinical notes from different specialties are often held in numerous
different locations and institutions across the region. Our clinical
audit was limited to notes held within the Peninsula Clinical
Genetics Service, so actions undertaken by other specialties may
have been missed. Third, we decided to focus our interviews on
individuals in whom we were unable to identify any outcomes
from the clinical audit, so our sample size for the qualitative phase
of the study was small. Additionally, only a small number of
interviews were performed, limiting our ability to draw general-
izable conclusions. Nonetheless, we were able to develop and
apply a systematic approach to evaluating outcomes across an
existing research cohort, and future research could utilize the
same methodology with larger sample sizes across multiple
genetics services (led by individuals embedded within each
Regional Genetics Service to access local patient notes), allowing
for greater comparative analysis. Additional research could also
expand to include information from clinical notes outside of
genetics, and potentially also explore similar themes in more
participants regardless of whether a clinical outcome had been
recorded in the notes.
Conclusion
Knowledge of the underlying molecular etiology of disease has
intrinsic value and is a worthwhile outcome of genetic testing and
research.34,35 Nonetheless, showing how that knowledge is used
and to what, if any, clinical purposes it can be put is of great
importance for assessing the wider medical, social, and economic
significance of a genetic diagnosis. This study aimed to system-
atically assess both clinical and nonclinical outcomes associated
with receiving a diagnosis through a subset of participants in the
DDD study. We show that receiving a diagnosis contributes to
clinically relevant outcomes in a high proportion of individuals
with developmental disorders and can streamline future clinical
care. Although a disease-specific treatment was available to only
a small number of individuals at the time of writing, the majority
of these treatments were associated with an improvement in
symptoms and more targeted treatments are likely to become
available in the future. Furthermore, through the interview
process, we found that even for those individuals without clinical
outcomes, participating in a genetics research study was a
positive experience and receiving a diagnosis can have significant
personal, emotional, and psychosocial outcomes for the patient
and their wider family.
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